TAIWANPLUS
17.1.2022 07:53:10 CET | Business Wire | Press release
TaiwanPlus, a new global English-language video streaming platform, launches a 2022 TaiwanPlus Original Series titled “Road to Legacy,” which is a 10-episode docuseries detailing the journey to fame of these 10 bands in Taiwan. On January 17, 2022, TaiwanPlus holds the world premiere at Legacy Taipei, with the docuseries launched exclusively and free to stream worldwide via www.TaiwanPlus.com on the same day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220116005075/en/
Since its inception, “TaiwanPlus strives to provide a platform to showcase the diverse, creative culture that flourished under Taiwan’s vibrant democracy. Following the positive reception from the TaiwanPlus Film Festival, which was an online curation of 10 iconic Taiwanese films, the platform now seeks to Bring Taiwan to the World through the country’s dynamic indie music scene,” indicates TaiwanPlus CEO Joanne Tsai.
Produced by TaiwanPlus, “Road to Legacy” is a co-production with Legacy Taipei, a live house institution in Taiwan that has hosted many renowned international and Taiwanese bands since 2009. Executive Producer Tien Tsung Ma says, “Contemporary Taiwanese music ranges from electronic music, rock, folk to hip-hop, and this docuseries is a timely snapshot of Taiwan’s music scene.” Shot over the course of 2.5 years, the docuseries unveils the truest side of these music artists, sharing their personalities, philosophy, and vision.
Among the ten bands featured, Tizzy Bac, ABAO and Namewee have garnered the most international presence. Tizzy Bac was established in 1999, offering a unique style of indie rock by integrating jazz, alternative rock, and electronic elements into their music. While indigenous Taiwanese R&B artist, ABAO, is hailed as a symbol of culture and heritage throughout Taiwan for her unique music. Malaysian artist and musician, Namewee, is known for pop and hip-hop, having garnered a following in East and South-East Asia as a passionate, outspoken activist for injustice and inequality. His work has been banned in China due to his song “Fragile Heart.”
The docuseries will be released in three installments, kicking off with the episodes on Tizzy Bac, 88BALAZ and Nighteentael on January 17th . The remaining episodes will be made available in February (PA PUN BAND, Dadado Huang and Sweet John) and March (Namewee, ABAO, The Next Big Thing and LINION). The full listing of “Road to Legacy” can be found at: https://tw.plus/Kb7nt
To coincide with this celebration of music, TaiwanPlus is also hosting an online campaign to crowd-source 12-sec videos with sound that embodies Taiwan on Instagram. Event details can be found here: https://tw.plus/CNV3b .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220116005075/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom